MYH9 and ovarian carcinoma: Recent studies showed that miR-6089 inhibited Wnt/β-catenin signaling and the associated EMT and reduced the expression of c-Jun and cell-cycle mediators via direct targeting of MYH9. The over-expression of MYH9 led to the upregulation of Wnt/β-catenin and EMT, c-Jun, and cell cycle mediators, thus abrogating the inhibitory effect of miR-6089 upregulation on ovarian cancer.